Seeking Alpha Buy Argues Execution And Valuation, But Master DCF And Soft Growth Keep CL A Hold

What happened

A Seeking Alpha article rates Colgate-Palmolive a Buy, citing improving execution, margin expansion, and a valuation discount relative to its historical average. The DeepValue master report, however, maintains a HOLD, noting the stock trades about 18% above its base-case DCF of $65.46. Recent fundamentals are mixed: Q2 2025 sales grew only 1% with flat volume, and North America operating profit fell 9% due to raw material costs and pricing dynamics. Hill's Pet Nutrition is highlighted as a growth driver, backed by premium innovation and expansion into fresh pet food, but that segment represents roughly 22% of sales. The article's optimism on emerging markets is tempered by FX headwinds, which have been a persistent drag.

Implication

The stock's P/E of 21.37 and premium to the DCF base case limit the margin of safety. However, if organic sales growth accelerates and margins expand as the article suggests, the intrinsic value could rise and justify a higher price. Key catalysts to monitor include Hill's premium innovation uptake, emerging market performance, and North America margin recovery. Until such improvements materialize, a HOLD rating with close monitoring is appropriate. Buying at current levels requires either a longer investment horizon or conviction in a re-rating driven by execution.

Thesis delta

The new article presents a bullish case based on execution and relative valuation, but it does not overcome the master report's DCF-based overvaluation signal and soft recent growth. The thesis remains HOLD, with a potential upgrade if organic sales and margins improve materially. The article's emphasis on Hill's and premium innovation offers a plausible upside path, but it needs confirmation in the numbers.